Comment on 'Jaw avascular bone necrosis associated with long-term use of biphosphonates' [3]

Annals of Oncology

Volumn 17, Issue 2, 2006, Pages 350-352

  Errante, Domenico ^a   Mannucci, N ^a   Bernardi, D ^a   Bianco, A ^a   Salvagno, L ^a  

^a Ospedale Civile   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; DOCETAXEL; GONADORELIN; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AVASCULAR NECROSIS; BONE METASTASIS; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL PROTOCOL; DRUG USE; DRUG WITHDRAWAL; HISTOLOGY; HUMAN; JAW DISEASE; LETTER; LONG TERM CARE; MALE; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; JAW; MALE; MIDDLE AGED; OSTEONECROSIS; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 31544443595     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj012     Document Type: Letter

References (9)

1. Sanna G, Zampino MG, Pelosi G, Nolè F, Goldhirsch A. Jaw avascular bone necrosis associated with long-term use of biphosphonates. Ann Oncol 2005; 16: 1207-1208.
2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115--1118.
4. Jones GR, Lehtinen T, Riphagen FE, von Roemeling R. Adverse event reporting of oral clodronate with emphasis on osteonecrosis of the jaw. Am Soc Clin Oncol 2005; 23: 77S (Abstr 799).
5. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4254.
6. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): Association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 2002; 1: 1191-1200.
7. Durie BGM, Katz M, McCoy J, Crowley J. Osteonecrosis of the jaws in myeloma: Time dependent correlation with Aredia and Zometa use. Am Soc Hematol 2004; 104: 216a (Abstr 756).
8. Damato K, Gralow J, Hoff A et al. Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws. Dockets Management, US Food and Drink Administration, June 2004; www.fda.gov/ohrms/dockets/ac/05/briefing/ 2005-409582_02_12-Novartis-Zometa-App-11.pdf.
9. Travis K, Zielinski SL. In Brief. J Natl Cancer Inst 2004; 96: 1572.